Wednesday, July 8, 2026

Patent intelligence · US

US 11612608

Methods of treating oral mucositis

granted A61KA61K31/555A61K45/06A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 17
Applicant portfolio 23
Patent details — US 11612608
Jurisdiction
US
Status
granted
Grant date
Mar 28, 2023
Expiration
Mar 23, 2043
Applicant
Galera Labs, LLC
Claims
14
CPC classes
A61K, A61K31/555, A61K45/06, A61P
View on Google Patents ↗

Quick answer

US 11612608 (Methods of treating oral mucositis) is held by Galera Labs, LLC. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Galera Labs, LLC
Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/555, A61K45/06, A61P, A61P1/02, A61P29/00

More from Galera Labs, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Expires Feb 6, 2045

    granted
  2. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Expires Nov 28, 2044

    granted
  3. US 12077549

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Galera Labs, LLC · Expires Aug 29, 2044

    granted
  4. US 11826373

    Methods for treatment of diseases

    Galera Labs, LLC · Expires Nov 23, 2043

    granted
  5. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Galera Labs, LLC · Expires Feb 10, 2042

    granted
  6. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Expires Jan 6, 2042

    granted
  7. US 11066433

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Galera Labs, LLC · Expires Jul 15, 2041

    granted

Frequently asked questions

What is US patent 11612608?

US 11612608 (Methods of treating oral mucositis) is held by Galera Labs, LLC. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11612608?

Galera Labs, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.

When does US 11612608 expire?

Our index shows an expiration date of Mar 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.